Human selenium-binding protein

Details Human selenium-binding protein Human selenium-binding protein

1998-06-02

2001-11-06

Huff, Sheela (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091200

Reexamination Certificate

active

06312895

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to nucleic acid and amino acid sequences of a novel human selenium-binding protein and to the use of these sequences in the diagnosis, prevention, and treatment of chemically-induced tissue damage, carcinogenesis, and cancer.
BACKGROUND OF THE INVENTION
The biological activity of selenium (Se) has been studied for over 40 years, but its precise function has not been fully elucidated. Originally identified as a highly toxic substance when ingested in large amounts, Se, usually in the form of disodium selenite (Na
2
SeO
3
), is now recognized as an essential trace element in eukaryotes and as a potent anticarcinogenic agent in a variety of animal models (Medina, D. and D. G. Morrison (1988) Pathol. Immunopathol. Res. 7:187-199; Lane, H. W. et al. (1989) In Vivo 3:151-160; Ip, C. (1986) J. Am. Coll. Toxicol. 5:7-20; Medina D. (1986) J. Am. Coll. Toxicol. 5:7-20; Combs, G. F. and S. B Combs (1986) in
The Role of Selenium in Nutrition
, Academic Press, San Diego, Calif.; pp. 413-461). Dietary Se affords protection against both the initiation and promotion of carcinogensis, and there is increasing epidemiological evidence to support its anticarcinogenic role in humans (Knekt, P. et al. (1990) J. Natl. Cancer. Inst. 82:864-868).
Se-containing proteins are detected in a broad spectrum of tissues in vivo and in cell lines in vitro by labeling with trace amounts of radioactive
75
Se (see for example, Morrison, D. G. et al. (1988) Anticancer Res. 8:51-64; Pederson, N. D. et al. (1972) Bioinorg. Chem. 2:33-45; Calvin, H. I. (1978) J. Exp. Zool. 204: 445-452; Motsenbocker, M. A. and A. L. Tappel (1982) Biochim. Biophys. Acta 709:160-165). Se is incorporated directly into proteins such as glutathione peroxidase, type I iodothyronine deiodinase, and selenoprotein P during translation. Incorporation of Se into these proteins is via the modified amino acid selenocysteine that is inserted into the nascent polypeptide in response to an in-frame UGA termination codon (Chambers, I. et al. (1986) EMBO J. 5:1221-1227; Takahashi, K. et al. (1990) J. Biochem. (Tokyo) 108:145-148; Berry, M. J. (1991) Nature 349:438-440; Hill, K. E. (1991) J. Biol. Chem. 266:10050-10053).
Some proteins do not contain selenocysteine but bind Se non-covalently. The precise nature of the binding site has not been established, but probably requires a pair of cysteine residues (Handel, M. L. et al. (1995) Proc. Natl. Acad. Sci. 92:4497-4501) because selenite is a potent oxidant of thiols. Additional structural elements must also play an important role in binding because only a limited number of
75
Se-labeled proteins can be detected by SDS-polyacrylamide gel electrophoresis after labeling in vivo.
Several Se-binding proteins from mouse, rat, and human have been identified and characterized (Bansal M. P. et al. (1990) Carcinogenesis 11:2071-2073; Bartolone, J. B. et al. (1992) Toxicol. Appl. Pharmacol. 113:19-29; Lanfear, J. et al. (1993) Carcinogenesis 14:335-340; Handel, M. L. et al., supra; Ishii, Y. et al. (1996) Toxicol Lett. 87:1-9; Spyrou, G. (1995) FEBS Lett. 368:59-63; Chang, P. W. G. et al., unpublished). Some of them belong to a family of highly homologous cytosolic proteins with similar molecular weights (ca. 54-58 kDa) and overlapping tissue distributions in the kidney, liver, lung, gastrointestinal tract, and male and female endocrine glands.
At least two related, but separately regulated genes, for Se-binding proteins are present in the mouse (Lanfear, J. et al., supra). One of these encodes the previously described ~58-kDa acetaminophen-binding protein (58-ABP). 58-ABP is thought to be a target for arylation by the widely used analgesic acetaminophen and its metabolites following acute drug overdose. Arylation can lead to life-threatening liver necrosis and to kidney and lung damage.
Se-binding proteins have been implicated in cellular growth control and the protection from carcinogenesis and cancer. For example, Morrison, D. G. et al. (1988; Carcinogenesis 9:1801-1810) have correlated the inhibition of DNA synthesis with the level of Se bound to proteins in mouse mammary epithelial cells in culture. Higher levels of bound Se are observed in non-growing cells than in growing cells, but the level of protein is unaffected. This suggests that Se binding modifies the activity of pre-existing proteins. Ishii, Y. et al. (supra) have also demonstrated that synthesis of an Se-binding protein is induced in rats treated with a known disease-causing polychlorinated biphenyl (PCB) compound.
Although not structurally related to the 54-58-kDa family of Se-binding proteins, the Fos and Jun subunits of the AP-1 transcription factor also bind Se and are thereby unable to bind to their DNA recognition sequence. As a consequence, transcription from AP-1-dependent promoters is inhibited by the addition of selenite to the culture media, whereas transcription from AP-2-dependent promoters is unaffected (Handel, M. et al., supra; Spyrou, G. et al., supra). The inhibition of transcription may thus provide an explanation for some of selenium's observed biological activities.
The discovery of polynucleotides encoding the selenium-binding protein, and the molecules themselves, provides the means to investigate the regulation of DNA synthesis and transcription by inorganic ions. Discovery of molecules related to the selenium-binding protein satisfies a need in the art by providing new diagnostic or therapeutic compositions useful in the diagnosis, prevention, and treatment of conditions and diseases associated with the activity of selenium-binding proteins such as liver necrosis and kidney or lung damage resulting from acetaminophen toxicity, as well as liver, kidney, lung, mammary, epithelial, gastrointestinal, and endocrine cancer.
SUMMARY OF THE INVENTION
The present invention features a novel human selenium-binding protein hereinafter designated HSEBP and characterized as having chemical and structural homology to selenium-binding proteins of fetal human heart, mouse, and rat. Accordingly, the invention features a substantially purified HSEBP having the amino acid sequence, SEQ ID NO:1.
One aspect of the invention features isolated and substantially purified polynucleotides that encode HSEBP. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2.
The invention also relates to a polynucleotide sequence comprising the complement of SEQ ID NO:2 or variants thereof. In addition, the invention features polynucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2.
The invention additionally features nucleic acid sequences encoding polypeptides, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotides that encode HSEBP. The present invention also features antibodies which bind specifically to HSEBP, and pharmaceutical compositions comprising substantially purified HSEBP. The invention also features the use of agonists and antagonists of HSEBP.


REFERENCES:
Knekt et al., “Serum Selenium and Subsequent Risk of Cancer Among Finnish Men and Women,”Journal of National Cancer Institute,82,(10):864-868 (1990).
Handel et al., “Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and FOS,”Proc. Natl. Acad. Sci. USA,97:4497-4501 (1995).
Bansal, “DNA sequencing of a mouse liver protein that binds selenium: implications for selenium's mechanism of action in cancer prevention,”Carcinogenesis,11(11):2071-2073 (1990) (GI 227630).
Bartolone et al., “Purification, Antibody Production, and Partial Amino Acid Sequence of the 58-kDa Acetaminophen-Binding Liver Proteins,”Toxicology and Applied Pharmacology,113:19-29 (1992).
Lanfear et al., “Different patterns of regulation of the genes encoding the closely related 56 kDA selenium-and acetaminohen-binding proteins in normal tissues and during carcinogenesis,”Carcinogenesis,14(3):335-340 (1993)(GI 298710).
Ishii et al., “Significant induct

Affiliated with

Also associated with

Rating

Human selenium-binding protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human selenium-binding protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human selenium-binding protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2602080